最新！美敦力又一高管变动

Core Insights - Nina Goodheart, the Senior Vice President and President of Medtronic's Structural Heart and Aortic business, announced her retirement after nearly 20 years with the company, marking the end of a significant career [1][3] Group 1: Leadership Background - Nina Goodheart joined Medtronic in 2007, initially focusing on the Cardiac Rhythm and Heart Failure (CRDM) market, and later held various key management positions [3] - Over the past five years, she led the Structural Heart and Aortic business, witnessing its evolution from a single product competition to a platform-based approach with expanded indications and long-term follow-up [3][5] Group 2: Business Progress During Tenure - Under her leadership, the core focus of Medtronic's Structural Heart business was clear, emphasizing the following: 1. Continuous advancement of the transcatheter aortic valve platform 2. Differentiated layout for transcatheter pulmonary valves 3. Promotion of clinical research and conceptual development [6] - The Evolut series of transcatheter aortic valve systems has seen ongoing iterations, maintaining a leading position in the global TAVR competition, while the Harmony transcatheter pulmonary valve system targets a niche market with high technical barriers [7] Group 3: Conclusion and Industry Implications - Goodheart's retirement is viewed as a normal conclusion of an executive career cycle rather than a sign of business pressure or strategic shifts [9] - The news holds value for industry stakeholders interested in how global leaders in the mature structural heart business achieve long-term stable operations [9]